Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT04653246Phase 2Active, not recruiting
- Start
- Jul 2021
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM). Started Jul 2021; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04653246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04653246.